8-K - Korro Bio, Inc. (0001703647) (Filer)

SCHEDULE 13G/A - Korro Bio, Inc. (0001703647) (Subject)

424B3 - Korro Bio, Inc. (0001703647) (Filer)

10-Q - Korro Bio, Inc. (0001703647) (Filer)

8-K - Korro Bio, Inc. (0001703647) (Filer)

DEFA14A - Korro Bio, Inc. (0001703647) (Filer)

DEF 14A - Korro Bio, Inc. (0001703647) (Filer)

SCHEDULE 13G/A - Korro Bio, Inc. (0001703647) (Subject)

EFFECT - Korro Bio, Inc. (0001703647) (Filer)

424B5 - Korro Bio, Inc. (0001703647) (Filer)

Citigroup initiated coverage of Korro Bio with a rating of Buy and set a new price target of $21.00

Raymond James upgraded Korro Bio from Mkt Perform to Outperform and set a new price target of $23.00

William Blair upgraded Korro Bio from Mkt Perform to Outperform

Piper Sandler upgraded Korro Bio from Neutral to Overweight and set a new price target of $30.00

H.C. Wainwright upgraded Korro Bio from Neutral to Buy and set a new price target of $20.00

Chardan Capital Markets upgraded Korro Bio from Neutral to Buy and set a new price target of $15.00

Cantor Fitzgerald upgraded Korro Bio from Neutral to Overweight and set a new price target of $21.00

Oppenheimer upgraded Korro Bio from Perform to Outperform and set a new price target of $22.00

RBC Capital Mkts downgraded Korro Bio from Outperform to Sector Perform and set a new price target of $8.00

Cantor Fitzgerald downgraded Korro Bio from Overweight to Neutral

4 - Korro Bio, Inc. (0001703647) (Issuer)

4 - Korro Bio, Inc. (0001703647) (Issuer)

4 - Korro Bio, Inc. (0001703647) (Issuer)

4 - Korro Bio, Inc. (0001703647) (Issuer)

3 - Korro Bio, Inc. (0001703647) (Issuer)

4 - Korro Bio, Inc. (0001703647) (Issuer)

4 - Korro Bio, Inc. (0001703647) (Issuer)

4 - Korro Bio, Inc. (0001703647) (Issuer)

4 - Korro Bio, Inc. (0001703647) (Issuer)

4 - Korro Bio, Inc. (0001703647) (Issuer)

CAMBRIDGE, Mass., May 27, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (NASDAQ:KRRO), a biopharmaceutical company leveraging a novel Oligonucleotide Promoted Editing of RNA (OPERA®) platform to develop a new class of genetic medicines for rare and highly prevalent diseases, today announced that Ram Aiyar, Ph.D., Chief Executive Officer and President, will present at the 2026 Jefferies Global Healthcare Conference being held in New York, NY on June 2nd- 4th, 2026. Dr. Aiyar's presentation will take place on Thursday, June 4, 2026, at 4:20 pm ET. About Korro Korro is a biopharmaceutical company leveraging a novel oligonucleotide promoted editing of RNA (OPERA®) platform to develop a ne

Potential best-in-class therapeutic delivered subcutaneously (GalNAc-conjugated oligonucleotide) for a debilitating genetic condition impacting both the liver and lungsDemonstrated >90% editing of SERPINA1 transcript in vivo translating into ~90% repaired functional alpha-1 antitrypsin (AAT) protein in plasma in a mouse model of AATDDemonstrated a near elimination of active Z-protein production while showing progressive clearance of pre-existing aggregates in a mouse model of AATDPre-clinical data highlighted the possibility of repeat dose therapy to achieve the functional equivalent of a DNA modification without altering the genome CAMBRIDGE, Mass., May 19, 2026 (GLOBE NEWSWIRE) -- Korro

CAMBRIDGE, Mass., May 15, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (NASDAQ:KRRO), a biopharmaceutical company leveraging a novel Oligonucleotide Promoted Editing of RNA (OPERA®) platform to develop a new class of genetic medicines for rare and highly prevalent diseases, today announced the grant of a non-statutory stock option to one newly hired employee. Korro granted the new employee a nonstatutory stock option to purchase 3,000 shares of Korro's common stock at an exercise price of $11.20 per share, the closing price per share of Korro's common stock as reported by Nasdaq on the grant effective date, May 13, 2026. The option has a ten-year term and vests over four years, with 2

Hosted virtual Analyst Day showcasing lead program KRRO-121's potential to be a first-in-class transformational treatment for hyperammonemia in patients with urea cycle disorders (UCDs) and hepatic encephalopathy (HE); regulatory filing for KRRO-121 expected in the second half of 2026Advanced early-stage research and development programs highlighted by a GalNac-conjugated oligonucleotide for alpha-1 antitrypsin deficiency (AATD); on track to announce development candidate in second quarter of 2026Executed oversubscribed $85 million private placement to support the achievement of value inflection points for multiple RNA editing clinical programs and extend cash runway into the second half of

CAMBRIDGE, Mass., May 05, 2026 (GLOBE NEWSWIRE) -- Korro, Bio, Inc. (Korro) (NASDAQ:KRRO), a biopharmaceutical company leveraging a novel oligonucleotide promoted editing of RNA (OPERA®) platform to develop a new class of genetic medicines for rare and highly prevalent diseases, today announced that Ram Aiyar, Chief Executive Officer and President, Jeffrey Cerio, SVP and General Counsel, Todd Chappell, Chief Operating Officer, and Loïc Vincent, Chief Scientific Officer, will participate in the following investor conferences: HCW 4th Annual BioConnect Nasdaq Investor ConferenceFormat: Fireside chat moderated by Mitchell Kapoor, Director and Senior Analyst, Biotechnology Equity Research, H.

American Society of Gene and Cell Therapy 29th Annual Meeting (ASGCT) TIDES USA 2026: Oligonucleotide and Peptide Therapeutics Conference3rd International Conference on Ureagenesis Defects and Allied ConditionsEuropean Association for the Study of the Liver (EASL) Congress 2026     CAMBRIDGE, Mass., April 16, 2026 (GLOBE NEWSWIRE) -- Korro, Bio, Inc. (Korro) (NASDAQ:KRRO),  a biopharmaceutical company developing a new class of genetic medicines based on editing RNA for rare and highly prevalent diseases, today announced oral and poster presentations highlighting data from its oligonucleotide delivery based RNA editing technology (OPERA®) will take place at the following scientific confere

CAMBRIDGE, Mass., April 10, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (NASDAQ:KRRO), a biopharmaceutical company developing a new class of genetic medicines based on editing RNA for rare and highly prevalent diseases, today announced the grant of a non-statutory stock option to one newly hired employee. Korro granted the new employee a nonstatutory stock option to purchase 15,000 shares of Korro's common stock at an exercise price of $13.46 per share, the closing price per share of Korro's common stock as reported by Nasdaq on the grant effective date, April 8, 2026. The option has a ten-year term and vests over four years, with 25% of the shares vesting on the first anniversary of

Nominated KRRO-121 development candidate for the potential treatment of hyperammonemia in patients with urea cycle disorders and hepatic encephalopathyAdvanced GalNAc-conjugated oligonucleotide for alpha-1 antitrypsin deficiency; on track to nominate development candidate second quarter of 2026Recent oversubscribed $85 million private placement extends cash runway into the second half of 2028 CAMBRIDGE, Mass., March 12, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (NASDAQ:KRRO), a biopharmaceutical company developing a new class of genetic medicines based on RNA editing for rare and highly prevalent diseases, today reported results for the fourth quarter and full year ended on Decem

CAMBRIDGE, Mass., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (NASDAQ:KRRO), a biopharmaceutical company developing a new class of genetic medicines based on editing RNA for rare and highly prevalent diseases, today announced that Ram Aiyar, Ph.D., Chief Executive Officer and President, will present at the TD Cowen 46th Annual Health Care Conference being held in Boston, MA at the Boston Marriott Copley Place on March 2nd – 4th, 2026. Dr. Aiyar's presentation will take place on Tuesday, March 3, 2026, at 11:10 a.m. ET. About Korro Korro is a biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevale

- Program to feature presentations from the company management about KRRO-121 for the potential treatment of hyperammonemia, a leading clinical hepatologist about ammonia-driven diseases, and a caregiver sharing perspectives on living with urea cycle disorder - CAMBRIDGE, Mass., Jan. 20, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (NASDAQ:KRRO) today announced that the company will host a virtual Analyst Day on Tuesday, January 27, 2026, from 8 a.m. – 10 a.m. ET, with members of the Korro management team, Bruce Scharschmidt, MD, hepatologist and former Chief Medical Officer of Hyperion Therapeutics, and Michelle Dinon, parent of a child impacted by a urea cycle disorder (UCD). Korro

4 - Korro Bio, Inc. (0001703647) (Issuer)

4 - Korro Bio, Inc. (0001703647) (Issuer)

4 - Korro Bio, Inc. (0001703647) (Issuer)

4 - Korro Bio, Inc. (0001703647) (Issuer)

4 - Korro Bio, Inc. (0001703647) (Issuer)

4 - Korro Bio, Inc. (0001703647) (Issuer)

4 - Korro Bio, Inc. (0001703647) (Issuer)

4 - Korro Bio, Inc. (0001703647) (Issuer)

4 - Korro Bio, Inc. (0001703647) (Issuer)

4 - Korro Bio, Inc. (0001703647) (Issuer)

SC 13G/A - Korro Bio, Inc. (0001703647) (Subject)

SC 13G/A - Korro Bio, Inc. (0001703647) (Subject)

SC 13G/A - Korro Bio, Inc. (0001703647) (Subject)

SC 13G/A - Korro Bio, Inc. (0001703647) (Subject)

SC 13G/A - Korro Bio, Inc. (0001703647) (Subject)

SC 13G/A - Korro Bio, Inc. (0001703647) (Subject)

SC 13G - Korro Bio, Inc. (0001703647) (Subject)

SC 13D/A - Korro Bio, Inc. (0001703647) (Subject)

CAMBRIDGE, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (NASDAQ:KRRO), a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, announced today the appointment of Loïc Vincent, Ph.D., as the Company's Chief Scientific Officer. "We are excited to welcome Dr. Vincent, whose extensive drug development experience and expertise in translating groundbreaking science into therapies will be instrumental in leading our scientific team and strategy," said Ram Aiyar, Ph.D., CEO and President of Korro. "He joins us at an important time as we advance multiple candidates i

CAMBRIDGE, Mass., Dec. 10, 2024 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation ("CAMP4") (NASDAQ:CAMP), a clinical-stage biotechnology company developing a pipeline of regRNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels across a range of genetic diseases, today announced the appointments of John Maraganore, Ph.D., and Rachel Meyers, Ph.D., as strategic advisors to the Company. For nearly 20 years, Dr. Maraganore served as the founding Chief Executive Officer and Director of Alnylam where he led the company's programs in RNA interference through global commercialization, resulting in the launch of the first four RNAi th

- Submitted regulatory filing for first-in-human clinical study of KRRO-110 in patients with alpha-1 antitrypsin deficiency (AATD) - Formed Clinical Advisory Board (CAB) of leading lung and liver experts and strengthened leadership team - Partnered with Novo Nordisk to develop up to two targets for cardiometabolic diseases leveraging Korro's proprietary OPERATM platform - Ended third quarter of 2024 with $169.1 million in cash, cash equivalents and marketable securities - Cash runway into the second half of 2026 expected to fund KRRO-110 through completion of a Phase 1/2 clinical study and progress additional pipeline candidates CAMBRIDGE, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Ko

CAMBRIDGE, Mass., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (NASDAQ:KRRO), a biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, today announced that the Board of Directors has appointed Katharine Knobil, M.D. as an Independent Director, effective immediately. Korro also announced that David Lucchino has stepped down from the Board. Dr. Knobil brings a wealth of experience in clinical development and regulatory affairs to Korro. With over 25 years in the pharmaceutical and biotech industries, she has played a pivotal role in advancing numerous therapeutics from early-stage develo

On track for regulatory filing for First-in-Human (FIH) study of KRRO-110 in patients with Alpha-1 Antitrypsin Deficiency (AATD) anticipated in the second half of 2024 Further strengthened balance sheet with closing of $70.0 million private placement (PIPE) on April 22, 2024, with cash and cash equivalents of approximately $206 million at close Cash runway into second half of 2026 to fund anticipated interim readout of KRRO-110 in the second half of 2025 and FIH study completion in 2026 Appointed Kemi Olugemo, M.D., FANN as Chief Medical Officer CAMBRIDGE, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (NASDAQ:KRRO), a biopharmaceutical company

Biotech veteran brings more than two decades of life science experience to Korro's Board CAMBRIDGE, Mass., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (NASDAQ:KRRO), a biopharmaceutical company focused on developing a new class of genetic medicines for both rare and highly prevalent diseases using its proprietary RNA editing platform, today announced the appointment of Rachel Meyers, PhD, to the Company's Board of Directors. "Rachel is one of the pioneers in advancing LNP and conjugate-based oligonucleotide therapies to the clinic and generating regulatory approvals," said Ram Aiyar, PhD, Chief Executive Officer of Korro. "With over two decades of research, development and